Boston Faces Rising Healthcare Costs Driven by GLP-1 Drugs

City officials propose utilization management to curb surging costs, but face pushback from unions

Mar. 17, 2026 at 2:37am

Got story updates? Submit your updates here. ›

Boston is bracing for a significant spike in health insurance costs, with premiums potentially increasing by nearly 23% in the upcoming fiscal year. The primary driver behind this surge is the growing use of GLP-1 medications, a class of drugs initially designed for diabetes treatment but increasingly popular for weight loss. City officials are grappling with the financial implications, as GLP-1 medications account for roughly 15% of the projected overall healthcare cost increase. To mitigate these rising costs, the Wu administration proposed 'utilization management' - requiring prior authorization from insurance providers before prescribing certain medications. However, the Public Employee Committee (PEC), representing unionized city employees and retirees, voted against the proposal earlier this month.

Why it matters

The proposed premium increases will directly impact the 55,000 members of the city's health insurance system, including employees, families and retirees. Boston isn't alone in facing this challenge, as several states and cities across the country are grappling with the escalating costs of GLP-1 medications. The city's limited financial flexibility, with projected revenue increases of only 1.5 to 2.5% for the next fiscal year, leaves fewer resources to absorb the rising healthcare costs.

The details

Currently, GLP-1 medications account for roughly 15% of the city's projected overall healthcare cost increase. Spending on these drugs is estimated at $31.6 million for the current fiscal year and is projected to climb to $47.4 million next year. Despite only approximately 7.7% of non-Medicare plan members utilizing GLP-1s for weight loss, this represents nearly 15% of the projected cost increase. The proposed 'utilization management' change was projected to save the city between $8 million and $9 million annually.

  • The city's health insurance costs are projected to increase by nearly 23% in the upcoming fiscal year.
  • Spending on GLP-1 medications is estimated at $31.6 million for the current fiscal year and is projected to climb to $47.4 million next year.

The players

Boston

The city facing a significant spike in health insurance costs due to the growing use of GLP-1 medications.

Wu administration

Proposed 'utilization management' - requiring prior authorization from insurance providers before prescribing certain medications - to mitigate the rising costs.

Public Employee Committee (PEC)

Representing unionized city employees and retirees, voted against the city's proposal to implement 'utilization management'.

Larry Calderone

President of the Boston Police Patrolmen's Association, expressed openness to negotiations to balance cost containment with access to necessary medications.

Elissa Cadillic

Cochair of the PEC, voiced concerns that the city's proposal could extend to all non-specialty medications, not just GLP-1s, and questioned the projected savings.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.